# A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.

Source: https://onco.cc/trials/nct06542250/  
OnCo record `nct06542250` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of AZD5492 in advanced solid tumours, run by AstraZeneca, now recruiting.

## Summary

A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies. is a phase 1/2 interventional study registered as NCT06542250 by AstraZeneca, with 174 participants planned, started 2024-09-18 and due to reach its primary completion in 2029-12-18. Interventions recorded: AZD5492.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06542250
- Phase: 1/2
- Setting: A Modular Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With Relapsed or Refractory B-Cell Malignancies (TITANium)
- Sponsor: AstraZeneca
- Enrolled: 174

## Sources

- ClinicalTrials.gov NCT06542250: https://clinicaltrials.gov/study/NCT06542250

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [AZD5492](https://onco.cc/drugs/azd5492/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct06542250.json